VOZMOZhNOSTI ANTIANGIOGENNOY TERAPII PRI RETsIDIVAKh GLIOM VYSOKOY STEPENI ZLOKAChESTVENNOSTI


Citar

Texto integral

Resumo

Рассматриваются современные возможности лечения глиом. Отмечается, что несмотря на проводимое агрессивнее лечение, включающее оперативное удаление опухоли и химиолучевую терапию, практически все глиомы рецидивируют. В качестве возможных вариантов лечения при возникновении рецидива или продолжающемся росте опухоли могут рассматриваться: повторная операция, повторная лучевая терапия, химиотерапия и комбинация методов. Исследования последних лет продемонстрировали высокую эффективность и безопасность бевацизумаба (Авастина) при лечении больных с рецидивами глиом высокой степени злокачественности после химиолучевой терапии при использовании как в монотерапии, так и в комбинации с иринотеканом. Представлен опыт применения бевацизумаба у девяти пациентов с анапластической астроцитомой или глиобластомой.

Bibliografia

  1. American Cancer Society. Cancer Facts and Figures 2009. Atlanta, Ga: American Cancer Society, 2009.
  2. Levin VA, Leibel SA, Gutin PH. Neoplasms of the central nervous system. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology, 5th ed, p 2022. Philadelphia, Lippincott-Raven, 1997.
  3. Дурнов Л.А., Голдобенко Г.В., Курмашов В.И. Детская онкология. М., 1997. С. 18, 196-225.
  4. Stiller CA, Nectoux J. International incidence of childhood brain and spinal tumours. Int J Epidemiol 1994;23:458.
  5. Grieg NH, Ries LG, Yancik R, et al. Increasing annual incidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst 1990;82:1621.
  6. Riggs JE. Longitudinal Gompertzian analysis of primary malignant brain tumor mortality in the U.S., 1962-1987: rising mortality in the elderly is the natural consequence of competitive deterministic dynamics. Mech Ageing Dev 1991;60:225.
  7. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10(5):459-66.
  8. Barker FG, Chang SM, Gutin PH, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998;42:709-20.
  9. Nieder C, Adam M, Molls M, et al. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 2006;60:181-93.
  10. Brandes AA, Fiorentino MV. The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest 1996;14:551-59.
  11. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for Phase II trials in patients with glioblastoma multiforme. Neuro Oncol 2007;9:29-38.
  12. Alba A, Brandes A, Tosoni E, et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol 2009;64(4):769-75.
  13. Perry J, Mason W, Belanger K, et al. The Temozolomide RESCUE study: a Phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma. Clin Oncol 2008;26(Suppl. 15):abstr. 2010.
  14. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-86.
  15. Zagzag D, Zhong H, Scalzitti JM, et al. Expression of hypoxia-inducible factor 1a in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000;88(11):2606-18.
  16. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006;1:97-117.
  17. Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8:610-22.
  18. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-710.
  19. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-48.
  20. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-45.
  21. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362(6423):841-44.
  22. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
  23. Duda DG, Jain RK, Willett CG. Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007;25:4033-42.
  24. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-48.
  25. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82.
  26. Folkins C, Man S, Xu P, et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007;67:3560-64.
  27. Gilbertson RJ, Rich JN. Making a tumour's bed: Glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007;7:733-36.
  28. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2:306-14.
  29. Stefanik DF, Fellows WK, Rizkalla LR, et al. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol 2001;55:91-100.
  30. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma. J Clin Oncol 1999;17(5):1516.
  31. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-Oncology 2005;7:369, abstr. 342.
  32. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol 2005;7:369.
  33. Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66:1258-60.
  34. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-29.
  35. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;31.
  36. Vredenburgh JJ, Wefel J, Cloughesy T, et al. Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. EJC 2009;7(Suppl.):495-96.
  37. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2008;27(5):740-45.
  38. Desjardins A, Reardon DA, Herndon II JA. Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas. Clin Cancer Res 2008;14:7068-73.
  39. Taillibert S, Vincent LA, Granger B, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 2009;72:1601-06.
  40. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-59.
  41. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-29.
  42. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 2008;112:2267-73.
  43. Cloughesy TF, Prados MD, Wen PY, et al. A Phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 2008;26(Suppl.):abstr. 2010b.
  44. Ullrich RT, Kracht LW, Jacobs AH. Neuroimaging in patients with glioma. Semin Neurol 2008;28:484-94.
  45. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with 18Ffluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007;25:4714-21.
  46. Chang SM, Clarke J, Wen P. Novel Imaging Response Assessment for Drug Therapies in Recurrent Malignant Glioma. ASCO 2009 Educational book 2009:107-111.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2009

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies